trusted by 100+ Patients

Onco D-CLARE by RGCC

Advanced Liquid Biopsy for Personalised Cancer Detection

Treatment Intro

What is Onco D-CLARE?

Onco D-CLARE is a cutting-edge liquid biopsy test developed by RGCC, designed to detect circulating tumor cells (CTCs) in the blood. This innovative test helps in the early detection of cancer, monitoring disease progression, and assessing treatment response—all through a simple blood sample.

‍

Why Choose it

Why Choose Onco D-CLARE?

Onco D-CLARE offers precise early detection of circulating tumour DNA, providing valuable insights into cancer presence, progression, and treatment response - all from a simple blood sample.
🌿

Non-Invasive and Highly Accurate 

Unlike traditional tissue biopsies, Onco D-CLARE requires only a blood sample, making it a safer and more comfortable option for patients.
🦠

Early Cancer Detection 

Detects cancer at its earliest stages, improving the chances of successful treatment and better patient outcomes.
🛡️

Real-Time Monitoring 

Helps track cancer progression and response to treatment, allowing for timely adjustments to therapy.
🧠

Personalized Cancer Care 

Provides critical insights into the type and characteristics of circulating tumor cells, aiding in targeted treatment planning.
⚖️

Advanced Technology 

Developed by RGCC, a global leader in cancer diagnostics and personalised medicine.
😴

Enhance Sleep & Recovery

Better gut health leads to deeper sleep, improved rest, and faster recovery.

The process

How Does Onco D-CLARE Work?

Onco D-CLARE utilises advanced molecular and cellular analysis techniques to identify and quantify circulating tumor cells in the bloodstream. These CTCs can indicate the presence of cancer, even before conventional imaging techniques can detect tumors. The test is particularly useful for patients with a high risk of cancer, those undergoing treatment, or individuals in remission who require continuous monitoring.

If you are looking for a revolutionary approach to cancer detection and monitoring, Onco D-CLARE by RGCC offers a reliable, non-invasive, and highly accurate solution.

Price : 4500 AED
Book a consultation

Perfect for

Is This Test Right for You?

Who Can Benefit from Onco D-CLARE?
Individuals at high risk of developing cancer
Patients currently undergoing cancer treatment
Individuals in remission who need regular monitoring
Healthcare providers seeking a reliable, real-time diagnostic tool

FAQs

01

What is the Onco D-CLARE test used for?

The Onco D-CLARE test is a non-invasive liquid biopsy test developed by RGCC to detect and analyse circulating tumor cells (CTCs) in the bloodstream. It supports early-stage cancer detection, tracks disease progression, and helps evaluate response to ongoing treatments.

02

How is this different from traditional cancer screening tests?

Unlike tissue biopsies or imaging, Onco D-CLARE only requires a blood sample. It identifies active cancer cells using cellular and molecular biology techniques—offering a non-invasive option for patients who require continuous monitoring or earlier diagnostic support.

03

Can Onco D-CLARE help detect cancer early?

Yes. The test can identify CTCs before tumours are detectable through imaging, making it suitable for patients at high cancer risk or those with a family history of cancer seeking to detect cancer early. It is considered an advanced cancer screening test due to its sensitivity and precision.

04

Who should consider taking the Onco D-CLARE test?

This test is well-suited for:

- Individuals at high risk of developing cancer

- Patients currently undergoing treatment

- Individuals in remission who need regular cancer monitoring

- Healthcare providers seeking a reliable tool for cancer diagnosis

05

What cancers is the test applicable to?

Onco D-CLARE is not specific to one cancer type and may be used across a variety of cancers, including solid tumours such as lung cancer. However, clinical context and physician recommendation should guide its use.

06

Does this test include gene expression analysis?

As part of its detailed CTC profiling, the test may involve gene expression analysis to help understand tumour characteristics, which can inform on early cancer detection. 

07

What are peripheral blood mononuclear cells, and are they used in this test?

Peripheral blood mononuclear cells (PBMCs) are cells that include lymphocytes (T cells, B cells, NK Cells) and monocytes. These cells are part of your immune system. Onco-D-clare isolates peripheral blood mononuclear cells from blood samples and uses machine learning to analyze over 90 genes, accurately classifying the samples as healthy or cancerous for early cancer detection.

08

How is the test transforming cancer care?

Onco D-CLARE supports a more proactive approach to oncology—allowing real-time monitoring, earlier detection, and insights that contribute to more tailored treatment strategies. It’s part of a broader movement in advanced cancer screening and transforming cancer care through precision medicine.

09

What is the price of the Onco D-CLARE test at Vervé Wellness?

The price for the Onco D-CLARE test at Vervé Wellness is AED 4,500, which includes sample collection and laboratory analysis through RGCC cancer testing, and a consultation with one of our Expert Doctors.